Tezepelumab is an investigational human IgG2 monoclonal antibody. It binds to TSLP to prevent TSLP-receptor interaction. [4] This mechanism prevents the release of cytokines via immune cells targeted by TSLP early in the inflammation cascade. [5] It has been suggested that tezepelumab could be an adjunct therapy for patients with a history of asthma exacerbations and uncontrolled asthma who have failed previous therapies. [6]

According to the World Allergy Organization, the term “allergic march” or “atopic march” describes the natural history of atopic manifestations characterized by a sequence of immunoglobulin E (IgE) antibody responses that produce certain clinical symptoms that can appear early in life, persist for years or decades and will cease spontaneously with time. [1] It has been identified that atopic dermatitis has its origins from these mechanisms. [2, 3]